GV was among the investors in a series A round led by Andreessen Horowitz closed three years after the gene therapy developer's launch.

The Atrium Health-backed clinical trial software provider increased its overall funding to over $88m in a round led by Insight Partners.

Genetic sequencing platform developer TwinStrand has secured $50m in a series B round led by Section 32, while Alexandria Venture Investments invested for a third time.

Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

UW spinout TwinStrand has completed a $50m series B round led by Section 32, while Alexandria Venture Investments invested a third time.

Opioid addiction care provider Groups Recover Together and healthcare management platform developer Vim each raised $60m, with Optum Ventures backing both rounds.

A decade or more after setting up the golden age of corporate venturing units were set up with a focus on life sciences and healthcare, such as US-listed conglomerate Alphabet’s GV (formerly known as Google Ventures) and US-listed drugs company Merck’s Global Health Innovation Fund (GHIF), and the returns have surpassed many expectations.

Workday Ventures has returned to back the telehealth platform developer’s series D round, which included Axa Venture Partners, Centene and GuideWell.